Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02561065
Other study ID # TANSNIP CNIC-VUMC-SANTANDER
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 25, 2015
Est. completion date January 30, 2020

Study information

Verified date March 2021
Source Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of TANSNIP-PESA is to determine in a population of asymptomatic bank employees with high and low imaging defined cardiovascular disease (CVD) risk the effectiveness of a comprehensive 3-year worksite-based lifestyle intervention consisting of 12 personalized lifestyle counseling sessions, a Fitbit physical activity tracker and a sit-stand Workstation.


Description:

We will study the effectiveness of a 30-month worksite-based lifestyle program aimed to promote cardiovascular health in participants having a high or a low degree of subclinical atherosclerotic plaque burden (SAPB), compared to standard care. Methods: We will conduct a randomized controlled trial (RCT) including middle-aged bank employees from the ´Progression of Early Subclinical Atherosclerosis´ (PESA) cohort, stratified by SAPB. Within each stratum, participants will be randomized 1:1 to receive a lifestyle program or standard care. The primary outcome measure is the adapted FUSTER-BEWAT CVD risk and lifestyle composite score and secondary outcome measures include physical activity, sedentary time, standing time, diet, smoking, anthropometric measures, blood biomarkers, self-rated health, work-related outcomes, healthcare consumption, program process measures and cost measures.


Recruitment information / eligibility

Status Completed
Enrollment 1020
Est. completion date January 30, 2020
Est. primary completion date January 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria: 1. Employees aged 40 to 60 years of the PESA (Progression of Early Subclinical Atherosclerosis) cohort study (48) from the Banco de Santander Headquarters in Madrid (Spain). 2. Employees to be included need to be 1 year before PESA 2/3 visit (-1/ +2 months deviation). 3. Employees that can be stratified into a high or low degree of imaging defined SAPB. High degree of imaging-defined SAPB will be defined as a high burden of atherosclerotic disease detected either by 2D ultrasound (upper tertile sum of maximum thickness of the plaques or coronary artery calcium score (CACS) by computed tomography = 1 point). Low degree of imaging-defined SAPB will be defined as having a CACS Agatston score of zero and no plaque by 2D ultrasound or being in the lowest two tertiles of plaque burden. Participants without plaque burden but with a BMI = 25, or; reporting at least one unhealthy lifestyle behavior in their last PESA visit (i.e., <150 min/wk of at least moderate intensity physical activity assessed by accelerometer, sitting >7 h/d as assessed by accelerometer, not meeting Mediterranean diet guidelines as assessed by a computerized dietary history tool previously developed and validated in the EPIC-Spain study and improved by ENRICA investigators, or smoking) will also be included in the low SAPB group. Exclusion Criteria: 1. Prior history of cardiovascular disease (myocardial infarction, angina pectoris, stroke, peripheral vascular disease, aortic aneurysm, angioplasty, heart surgery, atrial fibrillation, or any other heart disease). 2. Active treatment for cancer, history of transplant with active immunosuppressive or immunomodulator treatment. 3. Morbid obesity (body mass index =40 kg/m2). 4. Presence of any disease that decreases life expectancy to 3 years, or any condition that could affect adherence to the study procedures. 5. Participants are also excluded if they are pregnant or lactating women. 6. Employees without plaque burden, a healthy BMI and a healthy lifestyle will be excluded from the RCT.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Lifestyle intervention
Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner. The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition. A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday.

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III Icahn School of Medicine at Mount Sinai, Instituto de Salud Carlos III, VU University Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Adapted FUSTER-BEWAT score (Blood pressure, Physical activity, Sedentary time, Body Mass Index, Fruit and Vegetable Consumption and Smoking). Composite score consisting of: Blood pressure, Physical activity, Sedentary time, Body Mass Index, Fruit and Vegetable Consumption (as a proxy for overall diet) and Smoking. Changes between baseline, and Year 1, and Year 2 and Year 3.
Secondary Original FUSTER-BEWAT score. The initial FUSTER-BEWAT score will also be calculated in addition as a secondary outcome for future testing of psychometric properties of the adapted FUSTER-BEWAT score Changes between baseline, and Year 1, and Year 2 and Year 3.
Secondary Objective physical activity/sedentary time. Physical activity and sedentary time will be objectively assessed with an activPAL activity monitor (PAL technologies Limited, Glasgow, UK). Participants will also complete a short daily diary, reporting the exact wearing times. Changes between baseline, and Year 1, and Year 2 and Year 3
Secondary Self-reported lifestyle behaviors. The following questionnaires regarding physical activity and sedentary behavior will be administered: the International Physical Activity Questionnaire (IPAQ short form) (also at 4 and 6 months); the Occupational Sitting and Physical Activity Questionnaire (OSPAQ) (also at 4 and 6 months); the Workforce Sitting Questionnaire (WSQ) (also at 4 and 6 months); and single questions to assess average daily standing.
Data on dietary habits will be collected (also at 4 months) with the Mediterranean Diet Adherence Screener (MEDAS).
Smoking status will be a self-reported measure, as well as the average number of cigarettes or other tobacco products consumed daily.
Further, sleeping will be measured using the Sleep Habits Questionnaire developed by the Sleep Heart Health Study.
Changes between baseline, and Year 1, and Year 2 and Year 3
Secondary Physical assessments. Waist circumference, body height, body weight, and blood pressure. Changes between baseline, and Year 1, and Year 2 and Year 3.
Secondary Cardio-metabolic biomarkers. Complete blood count and chemistry panel as well as specific biomarkers related to subclinical atherosclerosis will be obtained. Changes between baseline, and Year 1, and Year 2 and Year 3.
Secondary Psychosocial assessment. Depression will be measured using the Center for Epidemiologic Studies Depression Scale (CES-D). Perceived stress will be measured using the Perceived Stress Scale (PSS).
Social support will be measured using the official Spanish translated ENRICHD Social Support Instrument (ESSI).
Job strain will be measured with an adapted version of the official Spanish translation of the Job Content Questionnaire (JCQ).
Quality of life will be self-reported using the EuroQol (EQ-5D-5L). Relaxation and detachment after work will be measured using the Recovery Experience Questionnaire.
Self-rated health will be assessed with the EuroQol Visual Analogue Scale (EQ VAS).
Vitality will be measured using the Vitality questionnaire (VITA-16).
Changes between baseline, and Year 1, and Year 2 and Year 3.
Secondary Personal characteristics. Sociodemographic information, including age, gender, marital status, working hours per week, employment status, job type, income and education level, will be assessed. Changes between baseline, and Year 1, and Year 2 and Year 3.
Secondary Economic evaluation. To evaluate the cost-effectiveness of the lifestyle program, sickness absenteeism, presenteeism (i.e., working while feeling ill) and healthcare consumption (e.g. general practitioner, allied health professionals, complementary medicine consumption) will be assessed every 3 months until 36 months after baseline. Sickness absenteeism and presenteeism will be assessed with items from the WHO Health and Work Performance Questionnaire (WHO-HPQ). Presenteeism is conceptualized in the WHO-HPQ as a measure of actual work performance in relation to best performance, irrespective of the presence or absence of health complaints. Sickness absenteeism will be self-reported using the WHO-HPQ in hours per month. Changes between 4 months up to 36 months (every 3 months measured).
Secondary Intervention process measures. Feasibility of the program using quantitative and qualitative methods on three levels: the participant, the psychologist and the stakeholder. Changes between baseline, 4 months and Year 1, and Year 2 and Year 3
See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Completed NCT05906797 - Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis. N/A
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Suspended NCT02932176 - Machine Learning for Handheld Vascular Studies
Recruiting NCT05158257 - Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity N/A
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Recruiting NCT06230406 - T-Mem GEne in Atherosclerosis
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02894931 - Effects of Dietary Interventions on Serum and Macrophage Atherogenicity N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
Completed NCT02224339 - New Technologies to Determine Carotid Plaque Vulnerability
Completed NCT03393377 - Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination N/A
Completed NCT02268513 - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
Completed NCT02377310 - Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography N/A
Completed NCT02116829 - Is There Room for Butter in a Healthy Diet? N/A